BioProject

Recurrent Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD) related to treatment with Secukinumab has not been previously documented. More...

Recurrent Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD) related to treatment with Secukinumab has not been previously documented. Despite adherence to treatment and avoiding hot springs, a plaque psoriasis patient experienced persistent NTM-PD relapses. There is a potential association between Secukinumab, an IL-17A inhibitor, and NTM disease, echoing anti-TNF biologics' NTM risk, indicating the urgent need for further research on pathogenic mechanisms and risk factors. Less...